There is only one therapeutic antibody approved by the FDA and the EMA for SLE therapy, namely belimumab, which neutralizes BAFF/BLyS and thereby decreases the number of newly formed B cells (139, 140). The gene discussed is TNFSF13B; the disease is systemic lupus erythematosus.